<DOC>
	<DOCNO>NCT01011374</DOCNO>
	<brief_summary>This prospective , single-center , non-randomized clinical study impact intravitreally administer ranibizumab ( Lucentis ) treatment vision-related functioning emotional well-being subject central branch retinal vein occlusion .</brief_summary>
	<brief_title>Impact Lucentis Psychological Morbidity Patients With Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Evidence central retinal vein occlusion , define document retinal hemorrhage four quadrant dilate vein , branch retinal vein occlusion , document clinical exam Age 18 year Central macular edema clinical exam well image central thickness â‰¥ 250 micron Visual acuity range 20/8000 20/40 Media clarity patient cooperation sufficient allow adequate test utilizing OCT FA No previous treatment might compromise confound assessment study outcomes Ability speak read English Acute illness cognitive impairment , opinion investigator , would interfere study requirement Concurrent ocular condition likely significantly compromise vision contribute macular compromise History grid/focal laser study eye History vitreal surgery Previous treatment triamcinolone acetonide either eye Previous use bevacizumab , pegaptanib , ranibizumab either eye Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder History cerebrovascular accident within 1 year prior Day 0 Inability comply study followup procedure Any cognitive defect result mental disease , previous injury , disease process may interfere interpretation study result Visual acuity well 20/40 Pregnancy ( positive pregnancy test ) lactation Inadequate contraception premenopausal woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Retinal vein occlusion</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Depression</keyword>
</DOC>